Patient Reviews in Myeloma E-Learning Faculty: Sundar Jagannath, MD | Robert Z. Orlowski, MD, PhD | Paul G. Richardson, MD CME credit hours: earn up to 8.0 credit hours While there are standard treatment paradigms for patients with multiple myeloma, the majority of patients eventually relapse. A number of new agents, including the immunomodulatory agents thalidomide and lenalidomide and the proteasome inhibitor bortezomib, have demonstrated impressive response rates in combination with established regimens and offer new hope for patients. Log on to review an interesting case study to earn .5 credits. Additionally, you have the opportunity to submit your own case studies for additional CME credits and the opportunity to be selected as a speaker for 1 of 2 upcoming Web conferences.
Management of Febrile Neutropenia and Anemia in Chemotherapy Patients: Clinical Practice Guidelines Update Faculty: Dwight Kloth, PharmD, FCCP, BCOP CME / CE credit hour: 1.0 Despite data showing the positive impact of treating febrile neutropenia and anemia in chemotherapy patients, a majority of patients still do not receive proper treatment. The European Cancer Anemia Survey (ECAS) reported that over 60% of the cancer-associated anemia patients did not receive any treatment for their anemia. Moreover, approximately 60,000 cancer patients are hospitalized annually with febrile neutropenia in the United States. This program will address strategies for treating chemotherapy induced anemia and febrile neutropenia, including identifying patients at risk and available treatment agents. Additionally, a review of the updated practice guidelines from ASCO, NCCN and EORTC and their practical applications will be discussed.
Chemotherapy-Induced Neutropenia Prevention: Implications of New Clinical Data and Guidelines Faculty: Jeffrey C. Crawford, MD | David C. Dale, MD | Gary H. Lyman, MD, MPH, FRCP (Edin) | Christopher R. Friese, RN, PhD, AOCN® CME / CE credit hour: 1.0
Chemotherapy-induced neutropenia has very serious and important clinical consequences in terms of medical care, quality of life, and economic factors for cancer treatment. Chemotherapy patients who develop neutropenia are at risk of developing febrile neutropenia, which is a medical emergency that requires immediate medical management. Febrile neutropenia has historically been treated through the use of prophylactic antibiotics, but their usefulness continues to be controversial and the incidence of febrile neutropenia continues to be high. The use of hematopoetic colony stimulating factors (CSFs) has improved the outcomes for patients who experience febrile neutropenia.
Applying Evidence to Practice: Recent Advances in the Management of Chemotherapy-Induced Neutropenia Faculty: Christopher R. Friese, RN, PhD, AOCN® | Joan M. Giblin, MSN, APRN-BC, AOCN® | Rebecca B. Donohue, MSN, RNCS, FNP, AOCN®, APNG | Anne Doyle, RN, MSN CE credit hour: 1.0 Neutropenia is the major dose-limiting toxicity associated with cancer chemotherapy and febrile neutropenia is associated with considerable morbidity, mortality, and cost. Colony Stimulating Factors, or CSFs, are used to reduce the severity and duration of chemotherapy-induced neutropenia and diminish the risk of febrile neutropenia and infection for patients receiving chemotherapy. The risk of neutropenia varies depending on the agent used and dose delivered. Predictive factors of febrile neutropenia have been identified for several types of malignancies. Identification of these risk factors when chemotherapy is planned can support the appropriate use of CSFs to reduce the risk of febrile neutropenia for patients.
The Conundrum of Rash in Management of EGFR Inhibitors(Accreditation Expired) Faculty: Roy S. Herbst, MD, PhD | Mario Lacouture, MD | Roman Perez-Soler, MD | Sandy Kurtin, RN, MS, AOCN®, NP CME / CE credit hour: 1.0 New therapies targeting the epidermal growth factor receptor (EGFR) have been used in the treatment of a variety of cancers. Although generally well tolerated, EGFR inhibitors are associated with the development of dermatologic reactions (e.g., papulopustular rash, xerosis, pruritus, periungual inflammation, and alopecia) in most patients. At present, little is known about the etiology of these reactions, and no evidence-based management guidelines have been set forth in the dermatologic literature.
All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.
Chemotherapy-Induced Neutropenia: Impact, Risks & Prevention